The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | MorningSun: subcutaneous mosunetuzumab in patients with previously untreated HTB follicular lymphoma
John Burke, MD, Rocky Mountain Cancer Centers, Aurora, CO, discusses results from the Phase II MorningSun study (NCT05207670) evaluating subcutaneous mosunetuzumab in previously untreated, high-tumor burden (HTB) follicular lymphoma. Dr Burke reports high response rates, manageable toxicity, and early evidence of deep molecular responses by circulating tumor DNA (ctDNA) analysis. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
